- Home
- LIVN
LIVN
LivaNova PLC
as of 03-23-2026 12:26pm EST
$63.55
+$1.44
+2.32%
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
| Founded: | 1987 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 3.5B | IPO Year: | 2015 |
| Target Price: | $72.43 | AVG Volume (30 days): | 891.2K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.45 | EPS Growth: | -483.62 |
| 52 Week Low/High: | $32.48 - $71.58 | Next Earning Date: | 05-06-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 9.43% | Revenue Growth (next year): | 6.85% |
| P/E Ratio: | -13.96 | Index: | N/A |
| Free Cash Flow: | 173.3M | FCF Growth: | +27.48% |
AI-Powered LIVN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 74.23%
74.23%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 25, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 25, 2026 · 100% conf.
AI Prediction BUY
1D
+1.01%
$71.00
Act: +1.01%
5D
+6.62%
$74.94
Act: -7.16%
20D
+10.61%
$77.75
Price: $70.29 Prob +5D: 100% AUC: 1.000
0001639691-26-000006
livn-20260225LIVANOVA PLC0001639691false00016396912026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2026
LivaNova PLC (Exact Name of Registrant as Specified in its Charter)
England and Wales001-3759998-1268150 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
20 Eastbourne Terrace London, W2 6LG United Kingdom (Address of Principal Executive Offices)
+44 20 33250660 (Registrant’s Telephone Number, Including Area Code)
N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name on each exchange on which registered Ordinary Shares - £1.00 par value per shareLIVNNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On February 25, 2026, LivaNova PLC (the “Company”) issued a press release announcing financial results for the quarter and full year ended December 31, 2025. The Company will host a business update conference call and webcast today, February 25, 2026, at 1 p.m. London time (8 a.m. Eastern Time), during which the Company will discuss the financial results. The conference call will be available through the LivaNova website at www.livanova.com/events.
A copy of the Company’s press release related to the foregoing matters is attached hereto as Exhibit 99.1. The information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
ExhibitDescription 99.1Press Release of LivaNova PLC dated February 25, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LivaNova PLC
Date: February 25, 2026By: /s/ Sarah K. Mohr
Name: Sarah K. Mohr Title: VP, Legal, Corporate & Securities and Company Secretary
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001639691-25-000146
livn-20251105LIVANOVA PLC0001639691false00016396912025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2025
LivaNova PLC (Exact Name of Registrant as Specified in its Charter)
England and Wales001-3759998-1268150 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
20 Eastbourne Terrace London, W2 6LG United Kingdom (Address of Principal Executive Offices)
+44 20 33250660 (Registrant’s Telephone Number, Including Area Code)
N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name on each exchange on which registered Ordinary Shares - £1.00 par value per shareLIVNNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2025, LivaNova PLC (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2025. The Company will host a business update conference call and webcast today, November 5, 2025, at 1 p.m. London time (8 a.m. Eastern Time), during which the Company will discuss the financial results. The conference call will be available through the LivaNova website at www.livanova.com/events.
A copy of the Company’s press release related to the foregoing matters is attached hereto as Exhibit 99.1. The information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
ExhibitDescription 99.1Press Release of LivaNova PLC dated November 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LivaNova PLC
Date: November 5, 2025By: /s/ Michael Hutchinson
Name: Michael Hutchinson Title: SVP, Company Secretary & Chief Legal Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001639691-25-000099
livn-20250806LIVANOVA PLC0001639691false00016396912025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2025
LivaNova PLC (Exact Name of Registrant as Specified in its Charter)
England and Wales001-3759998-1268150 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
20 Eastbourne Terrace London, W2 6LG United Kingdom (Address of Principal Executive Offices)
+44 20 33250660 (Registrant’s Telephone Number, Including Area Code)
N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name on each exchange on which registered Ordinary Shares - £1.00 par value per shareLIVNNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2025, LivaNova PLC (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025. The Company will host a business update conference call and webcast today, August 6, 2025, at 1 p.m. London time (8 a.m. Eastern Time), during which the Company will discuss the financial results. The conference call will be available through the LivaNova website at www.livanova.com/events.
A copy of the Company’s press release related to the foregoing matters is attached hereto as Exhibit 99.1. The information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
ExhibitDescription 99.1Press Release of LivaNova PLC dated August 6, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LivaNova PLC
Date: August 6, 2025By: /s/ Michael Hutchinson
Name: Michael Hutchinson Title: SVP, Company Secretary & Chief Legal Officer
Latest LivaNova PLC News
LIVN Breaking Stock News: Dive into LIVN Ticker-Specific Updates for Smart Investing
Business Wire
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
📈
AI Sentiment
Highly Positive
9/10
Zacks
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
📊
AI Sentiment
Positive
7/10
Compare LIVN vs Leading Stocks
See how LIVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LIVN LivaNova PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.